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Abstract
Background: KDM5B is a jmjc domain-containing histone demethylase which remove tri-, di-, and monomethyl
groups from histone H3 lysine 4 (H3K4). KDM5B has been determined as an oncogene in many malignancies.
However, its expression and role in hepatocellular carcinoma (HCC) remain unknown.
Methods: We detected the expression of KDM5B in HCC tissues and cell lines. Cell proliferation was performed to
reveal the role of KDM5B depletion on HCC cells both in vivo and in vitro. Flow cytometry was used to analyze the
cell cycle and chip analysis was conducted to determine the direct target of KDM5B.
Results: KDM5B is frequently up-regulated in HCC specimens compared with adjacent normal tissues and its
expression level was significantly correlated with tumor size, TNM stage, and Edmondson grade. Moreover, Kaplan-
Meier survival analysis showed that patients with high levels of KDM5B expression had a relatively poor prognosis.
Knockdown of KDM5B notably inhibits HCC cell proliferation both in vivo and in vitro via arresting the cell cycle at
G1/S phase partly through up-regulation of p15 and p27. Further molecular mechanism study indicates that
silencing of KDM5B promotes p15 and p27 expression by increasing histone H3K4 trimethylation in their promoters.
Conclusions: KDM5B could be a potentially therapeutic target, which provides a rationale for the development of
histone demethylase inhibitors as a strategy against HCC.
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Background
Mounting evidence indicates that epigenetic alterations
contribute significantly to the initiation and progression
of multiple human malignancies, including hepatocellu-
lar carcinoma [1–3]. As an important type of histone
modification, Histone methylation plays a central role in
regulating chromatin dynamics and transcription. This
modification has been linked to transcriptional activa-
tion or repression of gene expression, depending on the
specific residues that become methylated and the state
of methylation [4]. In general, lysine methylation on
H3K4, H3K36, H3K79 is associated with gene activation,
whereas lysine methylation on H3K9, H3K27, H4K20 is
linked to gene silencing [5]. Histone lysine methylation
is reversibly controlled by histone demethylases and
methyltransferases. Growing studies suggest that a num-
ber of histone demethylases are dysregulated in tumors
and can serve as oncoproteins [6–9].
Liver cancer is the sixth most common malignant dis-
ease worldwide but the third most frequent cause of
cancer-related death, with only 5 % of patients surviving
more than 5 years. In fact, about half of these cases and
deaths occur in China. Hepatocellular carcinoma (HCC)
represents the major histological subtype of primary liver
cancer, accounting for 70 to 85 % of the total liver cancer
worldwide, and its molecular etiology is heterogeneous
[10]. Numerous studies of molecules and signalling
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pathways related to the development of HCC have been
identified, yet the deep mechanisms underlying the onco-
genesis and cancer progression of HCC remain poorly
understood [11–15]. Therefore, a histone demethylase
that promotes HCC tumorigenesis could be an attractive
novel target for drug discovery. However, little is known
about the role of histone demethylases in HCC.
KDM5B is a jmjc domain-containing histone demethy-
lase, which belongs to KDM5 family. KDM5B was first
identified and characterized in 1999 when Lu found its
overexpression in human breast-cancer cell lines and
primary breast carcinomas [16]. Mammalian KDM5B
shows a restricted expression pattern in normal adult
tissues and is primarily present in the testis and brain
[17, 18]. However, KDM5B levels were found to be up-
regulated in a variety of human cancers such as bladder
cancer, [19] lung cancer, [20] colorectal cancer, [21]
prostate cancer, [22, 23] gastric cancer, [24] glioma, [25]
ovarian cancer [26] and malignant melanoma [27]. Since
KDM5B probably acts as a transcriptional regulator by
its ability to remove tri-, di-, and monomethyl groups
from H3K4, several cancer-associated genes regulated by
KDM5B have been identified, including tumor suppres-
sor gene BRCA1 that is repressed by KDM5B and tran-
scription factors E2F1 and E2F2 that are up-regulated by
KDM5B [19, 28, 29]. Besides, increasing studies revealed
that KDM5B was involved not only in tumor initiation,
but also in tumor progression such as invasion and me-
tastasis [30, 31]. Considering the growing evidence for
an important function of KDM5B proteins in cancer, it
becomes an attractive target for chemotherapeutic drug
design. Several preclinical studies suggest inhibition of
KDM5B histone demethylase can suppress tumorigen-
esis and provide strong rationale for development of
their inhibitors for use in cancer therapy [32–34].
We are particularly interested in KDM5B because we
found that it was the most significantly up-regulated his-
tone demethylase among 27 histone demethylase family
members by comparing their expression profiles be-
tween HCC and their adjacent normal liver tissues using
public database. Then we determined whether the highly
expressed KDM5B could contribute to the pathogenesis
of HCC. In the present work, we demonstrate that
KDM5B is frequently up-regulated in HCC specimens
and cell lines. Knockdown of KDM5B significantly in-
hibits cellular proliferation of HCC cells and arrests cell
cycle progression at the G1/S-phase. Moreover, the
effect of KDM5B knockdown on HCC cell proliferation
is mediated through upregulation of the cyclin-
dependent kinase inhibitors, p15 and p27. Furthermore,
our molecular mechanism study indicates that silencing
of KDM5B promotes p15 and p27 expression by increas-
ing histone H3K4 trimethylation in their promoters.
Collectively, our findings provide new insight into the
molecular pathogenesis of HCC and KDM5B may con-




All HCC specimens were obtained from HCC patients
who underwent surgical resection with informed consent
from May 2008 to October 2011. Both the tumor and ad-
jacent normal tissue were collected from each patient and
were frozen at −80 °C until processed. All patients had
negative histories of exposure to either chemotherapy or
radiotherapy prior to the surgical operation. The diagnosis
of HCC was validated by two individual pathologists. The
use of human tissues was approved by the institutional
ethics committee of Nanjing Medical University.
Cell culture and culture conditions
The human HCC cell lines (Hep-3B, MHCC-97 L, SMMC-
7721, SK-hep-1, MHCC-LM3, PLC/PRF/5, MHCC-LM6,
YY-8103, FOCUS, MHCC-97H, HepG2, Huh7, WRL-68,
Bel-7404, Bel-7405, L02) were obtained from the Chinese
National Human Genome Center at Shanghai. Cells were
grown in Dulbecco’s minimal essential medium (DMEM)
supplemented with 10 % FBS (Gibco, USA) and antibiotics
(50 U/ml penicillin and 50 μg/ml streptomycin) at an
atmosphere of 5 % CO2.
RNA extraction and quantitative real-time PCR
Total RNA was extracted from tissue or cell culture sam-
ples using TRIZOL reagent (Invitrogen) following the
manufacturer’s protocol and was reverse transcribed into
cDNA with a M-MLV reverse transcriptase kit (Promega,
USA). Quantitative real-time PCR was performed using
the Thermal Cycler Dice Detection System with the SYBR
Premix Ex Taq™ (Takara, Japan). All samples were done in
triplicate and the housekeeping gene β-actin was used as
an endogenous control. The following primers were used
to specially amplify the KDM5B gene and β-actin. For
KDM5B, forward: 5-GGTGAGCCAAAAACCTGGTA-3,
and reverse, 5-AATCACAAACTCCCCAGCAC-3; For β-
actin: forward: 5-AGAGCCTCGCCTTTGCCGATCC-3,
and reverse, 5-CTGGGCCTCGTCGCCCACATA-3.
RNA interference and cell transfection
KDM5B-specific small interference RNAs (siRNAs) were
designed and chemically synthesized (GenePharma,
China) to suppress endogenous KDM5B expression in
HCC cells: si-370, 5-CACGUAUCCAGAGACUGAAUG
AAdTdT-3; si-2531, 5-GGAUGCAGAGAAGUGUGCC
UCUGdTdT-3.
In addition, si-NC was also synthesized to act as a
negative control: si-NC, 5-UUCUCCGAACGUGUCA
CGUdTdT-3.
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The oligonucleotides encoding short hairpin RNAs
(shRNAs) for the continuous knockdown of endogenous
KDM5B were synthezised and inserted into pSUPER





AA-3; sh-NC containing irrelevant nucleotides was served
as a negative control: sh-NC, 5-GATCCCCTTCTCCG
AACGTGTCACGTTTCAAGAGAACGTGACACGTTCG
GAGAATTTTTGGAAA-3. All constructs were fully se-
quenced. The cells were then transfected with siRNA or
shRNA using lipofectamine 2000 (Invitrogen, USA) accord-
ing to the manufacturer’s instructions at cell density of 30-
50 %.
Cell proliferation
Transiently transfected HCC cells were seeded at a density
of 2000–5000 cells/well into 96-well plates and cultured
for a week. Cell growth was examined by Cell Counting
Kit-8 (Dojindo, Japan) according to the manufacturer’s
instructions. The absorbance value at a wave length of
450 nm was used as an indicator of cell viability.
Colony formation
Transfected HCC cells were plated at a density of 10,000–
50,000 cells/10-cm plate and maintained in the medium
with addition of 0.8 mg/ml G418 (Life Technologies, USA)
for colony formation. After 3 weeks, colonies stained with
0.1 % crystal violet were counted and photographed.
For the soft agar colony formation assay, 2000–5000
transfected cells were plated and grown in the 24-well
plate with the medium containing 1 % base agar and
0.5 % top agar. After 3 weeks, all colonies were counted
and photographed under a dissecting microscope.
Experiment in vivo
Animal care and euthanasia were approved by the
Nanjing medical University animal studies committee.
Fifteen BALB/c nude mice were randomly divided into
three groups including the negative control group and two
KDM5B knockdown groups. Hep3B cells transfected with
sh-KDM5B or negative control were selected under
0.8 mg/ml G418 (Life Technologies, USA) for 3 weeks.
Then the stably transfected cells were harvested at a con-
centration of 1 × 107 cells/ml. Of the suspending cells,
0.1 ml was inoculated subcutaneously into either side of
the posterior flank of the 4–6-week-old BALB/C nude
mice. Xenografts in each group were observed periodically
after injection. Nude mice were killed by cervical disloca-
tion after 3 weeks and the xenografts were peeled off sub-
cutaneously. The weight of the xenografts in each group
was compared and used for further analysis.
Cell cycle analysis
Flow cytometry was performed to analyze the cell cycle.
Serum starvation was used to induce cell cycle syn-
chronization before cell transfection. At 48 h after
transfection with KDM5B siRNAs duplexes, cells were
harvested as single cell suspensions. After fixation in 70 %
ethanol for 1 h at −20 °C, cells were washed and resus-
pended in PBS, followed by incubation with propidium
iodide (10 mg/ml) and RNase A (10 mg/ml) for 30 min at
4 °C. FACSCalibur fow cytometer, CellQuest (BD Biosci-
ences, USA) was used to calculate the percentage of cells
in each phase.
Protein extraction and western blot analysis
Total protein was extracted using cell lysis buffer
containing 50 mM Tris–HCl (pH 6.8), 2 % SDS, 10 %
2-mercaptoethanol, 10 % glycerol, and protease inhibitor
cocktail (Sigma, USA). Protein samples (20 mg) were re-
solved using SDS-PAGE and transferred onto a nitrocellu-
lose membrane. The membrane was blocked with 5 %
milk in TBS for 2 h at room temperature. After incubation
with the appropriate primary antibody overnight at 4 °C,
membranes were washed and incubated with the IRDye
800cW or 680RD secondary antibodies in TBST for 2 h at
room temperature. Then the protein bands of interest
were visualized with the Odyssey system (LI-COR, USA).
The specific antibodies used in our study were as follows:
anti-KDM5B (Abcam, British), anti-p15 (CST, USA),
anti-p27 (CST, USA), anti-H3K4me2 (CST, USA), anti-
H3K4me3 (CST, USA), anti-total-H3 (CST, USA), and
anti-β-actin (CST, USA).
Chromatin immunoprecipitation assays (ChIP)
The ChIP assays were performed by using EZ-ChIP KIT
according to the manufacturer’s instruction (Millipore,
USA). The control and KDM5B siRNA-treated Hep3B
and Focus cells were treated with formaldehyde and in-
cubated for 10 min to generate DNA-protein cross-links.
Then the cell lysates were sonicated to generate chroma-
tin fragments of 200–1000 bp. The antibodies against
KDM5B and trimethylated H3-K4 (H3-K4me3) were
used to precipitate DNA fragments bound by their cor-
responding elements. The protein-DNA complex was
collected with protein A Sepharose beads (Millipore,
USA), eluted, and reverse cross-linked. Following treat-
ment with Protease K (Sigma-Aldrich, USA), the samples
were extracted with phenol-chloroform and precipitated
with ethanol. The recovered DNA was resuspended in TE
buffer and used for the PCR amplification.
Statistical analysis
All statistical data were carried out using Statistical
Program for Social Sciences 18.0 software (SPSS, USA)
and presented with Graphpad prism 5.0 (GraphPad
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Software, CA). The significance of differences between
groups was evaluated with Student’s t-test and χ2 test as
appropriate. DFS and OS rates were calculated by the
Kaplan-Meier method with the log-rank test applied for
comparison. Two-sided p-values were calculated, and a
probability level of less than 0.05 was considered to be
statistically significant.
Results
KDM5B is frequently up-regulated in HCC tissues and
cell lines
To explore a histone demethylase with oncogenic char-
acteristics for HCC, We first analyzed expression profiles
of a number of histone demethylase genes in a subset of
HCC samples by using public GEO Profiles database
(GSE 25097) and found that KDM5B was the most
obvious up-regulated histone demethylase with at least
2-fold up-regulation in 40 % HCC specimens (Fig. 1a).
To verify the data from public database, we used quanti-
tative RT-PCR to measure KDM5B mRNA levels of 50
paired HCC samples and found significantly higher
expression levels of KDM5B in HCC tissues compared
with their corresponding non-tumorous liver tissue
(Fig. 1b). Eight pairs of typical cases were illustrated by
western blot (Fig. 1c). Subsequently, we analysed the ex-
pression profiles of 15 widely used HCC cell lines and
the resulting data showed that the expression of KDM5B
was elevated in most of HCC cell lines when compared
to the normal human liver cell line L02 and normal
adult liver tissue (Fig. 1d). Collectively, these results sug-
gested that KDM5B expression is up-regulated in human
HCC tissues and cell lines.
KDM5B mRNA level is associated with clinicopathologic
characteristics of HCC and high KDM5B expression
predicts poor survival in HCC patients
To investigate the clinical impact of elevated KDM5B
expression in HCC, we assessed the association between
KDM5B mRNA levels and clinicopathologic parameters
in additional 100 patients with HCC. All HCC samples
were divided into KDM5B high expression group (n = 50)
and low expression group (n = 50), median was used as
cut-off value. Significant correlations were found between
KDM5B expression and tumor size, TNM stage, and
Edmondson grade, suggesting that KDM5B might have a
stimulatory role in the progression of HCC (Table 1).
Moreover, Kaplan-Meier survival analysis was used to de-
termine whether the expression of KDM5B was associated
Fig. 1 KDM5B expression is obviously up-regulated in HCC tissues and cell lines. a Expression profiles of a number of histone demethylase genes
in a subset of HCC samples from public GEO Profiles database. b Validation of the aberrantly up-regulated KDM5B in 50 pairs of HCC and the
corresponding adjacent non-cancerous liver (non-HCC) by quantitative real-time PCR. Expression of β-actin was used as an internal control and
P value was calculated by student’s t test. (***, P < 0.001). c Representative results of up-regulation of KDM5B in 8 pairs of HCC (c) and the adjacent
non-HCC liver tissue (N) by western blot. d The expression levels of KDM5B was determined by real-time PCR in 15 HCC cell lines as well as the normal
human liver cell line L02 and normal adult liver tissue, with β-actin as an internal control
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with disease-free survival (DFS) and overall survival (OS)
of the HCC patients. The results showed that patients
with high expression of KDM5B had a worse DFS than
those with low KDM5B expression (P = 0.0005) (Fig. 2a).
Likewise, a statistically significant association between
high KDM5B expression and short OS was also demon-
strated in HCC patients (P = 0.0006) (Fig. 2b). These
results collectively implied that up-regulation of KDM5B
can predict poor survival of HCC.
KDM5B knockdown inhibits cell viability and colony
formation
To determine whether KDM5B is necessary for the pro-
liferation of HCC cells, we used chemically synthesised
siRNAs and constructed the corresponding shRNA plas-
mids to knockdown endogenous KDM5B in 2 HCC cell
lines (Hep3B and Focus) with relatively high KDM5B
level. The efficient inhibition of KDM5B expression in
siRNA-treated cells was verified using quantitative real-
time PCR (Fig. 3a). As expected, we observed significant
growth suppression of HCC cell lines treatd with
siRNAs in comparison with the si-NC-transfected cells
(Fig. 3b). Moreover, KDM5B depletion by shRNAs
substantially inhibited the colony formation of KDM5B-
overexpressing HCC cell lines compared to the control
shRNA-NC-infected cells (Fig. 3c). Furthermore, down-
Table 1 Correlation between KDM5B expression and










Male 65 34 31 0.6753
Female 35 16 19
Age (years)
≥ 50 60 32 28 0.5406
< 50 40 18 22
Tumor size (cm)
≥ 5 55 36 19 0.0012**
< 5 45 14 31
Tumor number
Solitary 62 33 29 0.5368
Multiple 38 17 21
HBsAg
Positive 76 40 36 0.4829
Negative 24 10 14
HCV
Positive 11 8 3 0.1997
Negative 89 42 47
Cirrhosis
Positive 82 43 39 0.4356
Negative 18 7 11
ALT (U/L)
≥ 45 46 26 20 0.3158
< 45 54 24 30
AFP (ng/ml)
≥ 20 57 31 26 0.4193
< 20 43 19 24
TNM stage
I + II 56 21 35 0.0085**
III + IV 44 29 15
Edmondson grade
I + II 59 23 36 0.0142*
III + IV 41 27 14
The median expression level of KDM5B was used as the cut off
*P < 0.05
**P < 0.01 between the two groups
Fig. 2 KDM5B expression was correlated with the DFS or OS of
HCC patients. a Patients with high KDM5B expression had a
worse disease-free survival (DFS) than patients with low KDM5B
expression. b Patients with high KDM5B expression had a worse overall
survival (OS) than patients with low KDM5B expression.100 HCC samples
were divided into KDM5B high expression group (n= 50) and low
expression group (n= 50), median was used as cut off
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regulation of kdm5B decreased the anchorage-independent
growth of these HCC cell lines in soft agar and signifi-
cantly reduced the number of larger colonies compared to
the cells transfected with the negative control shRNAs
(Fig. 3d). These collective data indicated that endogenous
expression of KDM5B is essential for maintaining cell pro-
liferation and colony formation in HCC cells and can
function as an oncoprotein in HCC.
Fig. 3 KDM5B knockdown inhibits HCC cellular proliferation and colony formation in vitro. a and b Knockdown of endogenous KDM5B suppresses the
proliferation of Hep-3B and Focus cell lines. The silencing efficiency of two siRNA (si-370, si-2531) against endogenous KDM5B was evaluated by real-time
PCR, where si-NC was used as a negative control. c KDM5B RNAi suppressed colony formation in Hep-3B and Focus cells, as shown by representative
plates of cells transfected with the KDM5B shRNA constructs and shRNA-NC control. The histograms represent mean with standard deviation of
colonies from triplicate tests. d KDM5B RNAi limited colony formation of Hep-3B and Focus cells in soft agar. The histograms represent mean with
standard deviation of colonies from triplicate tests. Here all experiments were performed independently 3 times. A t test was used to evaluate the
statistical significance of these experiments, as compared to the control. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Original magnification, ×40
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KDM5B knockdown suppresses tumorigenicity and
reduces tumor burden
To further determine the effect of KDM5B knockdown
on tumorigenicity in vivo, we performed a subcutaneous
xenograft tumor model in nude mice. Hep-3B cells were
transfected with pSUPER-shRNA plasmids, then these
cells were harvested and injected into the flanks of nude
mice. The diameters of the tumors were measured every
3 days. As expected, pSUPER-sh370 and pSUPER-
sh2531 were able to significantly suppress tumorigen-
icity, resulting in obvious reductions in tumor weight
and volume compared to the negative controls pSUPER-
shNC (Fig. 4a-c). All these results verified that KDM5B
knockdown inhibited HCC cell xenograft formation and
growth in vivo.
KDM5B knockdown arrests the cell cycle at G1/S phase in
HCC cells
To further assess the mechanism of growth suppression
induced by KDM5B knockdown, we performed a flow
cytometry to analyze the cell cycle status of cancer cells
of cells with or without KDM5B depletion. The results
showed that the fraction of HCC cells at the G1 phase
was significantly higher in cells treated with siKDM5B
than in those treated with control siRNAs, while the
proportion in S phase was remarkably decreased (Fig. 5a
and b). To investigate whether knock-down of KDM5B
suppressed proliferation in HCC cells through apoptosis
and senescence, we performed FACS assays and
senescence-associated (SA) β-galactosidase (SA-β-gal)
analysis, respectively. However, no apparent difference was
observed in apoptotic cells (Additional file 1: Figure S1A)
and senescent cells (Additional file 1: Figure S1B) between
Hep-3B cells with or without KDM5B knockdown. Taken
together, these data demonstrated that KDM5B affects
HCC cell proliferation through cell cycle arrest, other than
inducing cell apoptosis or senescence.
KDM5B negatively regulates the expression of the p15
and p27
The regulation of G1-S phase transition is governed by
cyclins, cyclin-dependent kinases (CDKs), and cyclin-
dependent kinase inhibitors (CDKIs). So we detected
whether the expression of these genes was altered by
KDM5B knockdown in HCC cells using quantitative
real-time PCR. Interestingly, KDM5B depletion notably
increased the mRNA expression of p15 and p27 in the
Hep3B cell line. In contrast to p15 and p27, expression
of other genes such as p14 and p16 were inconsistently
or weakly affected by KDM5B knockdown. Similar re-
sults were obtained in the Focus cell line, indicating that
KDM5B regulates p15 and p27 mRNA expression in
multiple HCC cell lines (Fig. 6a). In addition, western
blot results demonstrated that the protein levels of p15
and p27 were also increased with KDM5B silencing in
Hep3B and Focus cells (Fig. 6b). We further examined
whether p15 and p27 mRNA levels were in relation to
KDM5B expression in 15 HCC cell lines by the Pearson
correlation analysis. Results showed that CDKI expres-
sion was negatively correlated with KDM5B expression
in the examined HCC cell lines (Fig. 6c). These data sug-
gested that p15 and p27 expression can be negatively
regulated by KDM5B in HCC cells.
Loss of the KDM5B occupancy was coupled with elevated
H3-K4 trimethylation on the p15 and p27 promoters in
KDM5B-depleted HCC cells
Since p15 and p27 expression were regulated by KDM5B
at both mRNA and protein levels, we speculated
whether these 2 genes are direct targets of KDM5B.
Fig. 4 KDM5B knockdown reduces the tumor burden in vivo.
a-c Both pSUPER-sh370 and pSUPER-sh2531 knockdown of KDM5B
suppressed the tumorigenicity of Hep-3B cells in nude mice (n = 6),
as compared with the negative control pSUPER-shNC. Tumors were
weighed (b) and tumor volume (c) was evaluated every 3 days. The
data were presented as the mean ± SD (n = 3), ** P < 0.01
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Chromatin immunoprecipitation assay was thus per-
formed to determine an association of KDM5B with p15
and p27 promoters. In the cells treated with control
siRNA, KDM5B occupancy on the promoter region of
the 2 genes was readily detectable. In contrast, knocking
down KDM5B abolished its association with these
promoter sequences (Fig. 7a and b). Moreover, KDM5B
depletion led to significantly enhanced H3-K4 trimethy-
lation at the proximal promoter region of p15 and p27
genes (Fig. 7a and b). These consistent results suggested
that p15 and p27 are candidate direct target genes nega-
tively regulated by KDM5B in HCC cells.
KDM5B regulates HCC cell growth in a p15- and
p27- dependent manner
To determine whether p15 and p27 are key mediators of
KDM5B’s function in cellular proliferation, we assessed
the colony formation when both KDM5B and p15 or
p27 were simultaneously silenced via RNAi (Fig. 8a).
Interestingly, RNAi against p15 or p27 could largely
Fig. 5 KDM5B knockdown causes cell cycle arrest in G0/G1 phase. a and b The cell cycle analysis was performed after Hep-3B cells or Focus cells
were infected with siRNAs. Representative cell cycle distributions were shown and the histogram columns represent the average percentages of
G0/G1, S and G2/M phases. The data were presented as the mean ± SD (n = 3), NS, not significant, **P < 0.01, and ***P < 0.001
Wang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:37 Page 8 of 13
rescue the inhibitory effect of KDM5B knockdown on
colony formation in Hep3B (Fig. 8b) and Focus (Fig. 8c)
cells. These results indicated that the inhibition of cellu-
lar proliferation caused by KDM5B knockdown are
dependent largely on the up-regulation of p15 and p27.
Discussion
Hepatocellular carcinoma (HCC) is a worldwide malig-
nancy with a high mobility and mortality, especially in
China. The long-term survival rate for HCC remains
poor despite advanced therapeutic modalities and strat-
egies such as surgery, chemotherapy and radiotherapy.
Therefore, better understanding of the pathogenesis of
HCC and exploring novel therapeutic approaches against
drug targets are urgently needed.
Emerging evidence has indicated that a number of his-
tone methylation modifiers are dysregulated in tumors
and are critical for oncogenic phenotypes [35–38].
Jumonji C (JmjC) domain containing protein has been
identified to possess histone demethylase activity and
Fig. 6 KDM5B depletion-mediated induction of CDKI p15 and p27. a KDM5B depletion obviously increased the mRNA expression of p15 and p27
in Hep3B and Focus cell line. b KDM5B depletion notably increased the protein expression of p15 and p27 in Hep3B and Focus cell line. c Pearson
correlation analysis demonstrated the negative correlation between p15, p27 and KDM5B
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play important roles in cancer ignition and progression.
KDM5B, a member of the KDM5 family of proteins, has
recently been shown to possess H3-K4 demethylase ac-
tivity and exhibit oncogenic activities in several human
cancers. However, whether and how KDM5B is involved
in HCC progression is still unknown. Here, we provided
evidence that KDM5B was frequently up-regulated in
HCC tissues and that its expression in HCC cells is re-
quired to repress the transcription of multiple CDKIs
and to maintain sustained proliferation of cancer cells.
These immortal malignant cells undergo cell cycle arrest
and lose clonogenic potentials when KDM5B is knocked
down. Therefore, we speculated that the aberrant ex-
pression of KDM5B might be an important epigenetic
factor involved in the pathogenesis of HCC.
The effect of KDM5B inhibition on cell proliferation is
not cell type or context-specific, since we observed simi-
lar phenotypic changes in two different HCC cell lines
(Hep3B and Focus) upon KDM5B knockdown. Analysis
of cell cycle distribution revealed that KDM5B depletion
led to an obvious arrest at G0/G1 phase. Moreover,
results of FACS assays and senescence-associated (SA)
β-galactosidase (SA-β-gal) analysis excluded the possibil-
ity that KDM5B knockdown affected HCC cell proli-
feration through apoptosis or senescence. Therefore, we
decided to lay emphasis on some molecules involved in
the regulation of G1-S phase transition. P15, a member
of the INK4 family of cyclin-dependent kinase inhibitors,
is capable of inducing cell cycle arrest in G1 phase and
has been identified as a tumor suppressor, as well as the
other two INK4 family members p16 and p14 [39, 40].
P27 is also a cyclin-dependent kinase inhibitor and can
block the cell cycle at G0/G1 phase upon differentiation
signals or cellular insult. The degradation of p27 protein
is required for the cellular transition from quiescence to
the proliferative state [41–43]. H3-K4 methylation and
demethylation are prevalent marks associated with tran-
scription activation and repression. KDM5B, which is a
histone demethylase specific for di- and trimethylated
H3-K4, is believed to act as a transcriptional repressor
partly through inhibiting H3-K4 methylation at its target
promoters. Actually, KDM5B has been implicated in si-
lencing tumor suppressor genes such as BRCA, p21 and
TIEG1 through its demethylase activity [25, 28, 44]. Ac-
cording to this model, our findings provide evidence that
p15 and p27 are all the direct targets of KDM5B in
HCC. First, our current results demonstrated that deple-
tion of KDM5B notably up-regulated the mRNA and
protein expression of p15 and p27. In addition, KDM5B
was associated with the proximal promoter sequences of
these 2 genes. When knocked down, KDM5B occupancy
on these promoters was lost, which was coupled with
Fig. 7 Regulation of the p15 and p27 promoter occupancy on their promoters region by KDM5B. a and b The KDM5B occupancy and trimethylation
status of histone H3 (H3K4Me3) at the promoters of p15 and p27 genes. C and R: Control siRNA and KDM5B siRNA, respectively. ChIP was used to
precipitate KDM5B and H3K4Me3-bound DNA followed by PCR amplification with the specific primers spanning p15 and p27 promoters. Input: 2 % of
total chromatin materials were PCR amplified with the same primers
Wang et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:37 Page 10 of 13
highly elevated H3-K4 trimethylation locally. Moreover,
loss of p15 and p27 function could largely rescue the anti-
proliferation effect of KDM5B depletion on HCC cells, al-
though the recovery was not 100 % efficient compared with
control cells. Given the fact that these 2 proteins are tumor
suppressors by negatively regulating cell cycle progression,
we conclude that up-regulation of KDM5B may act as a
proto-oncogene which functions at least partially by repres-
sing tumor suppressors through its demethylase activity.
Conclusions
In conclusion, our results suggest that KDM5B is over-
expressed in the vast majority of HCC specimens and
that its depletion leads to highly impaired clonogenesis
and cell cycle arrest through up-regulation of p15 and
p27. Therefore, KDM5B could be a potentially thera-
peutic target, which provides a rationale for the develop-
ment of histone demethylase inhibitors as a strategy
against HCC.
Additional file
Additional file 1: Figure S1. Knockdown of KDM5B has no obvious
effect on apoptosis and senescence of HCC cells. (A) FACS assays was
performed to detect the difference in apoptotic cells between Hep-3B
cells with or without KDM5B knockdown. (B) Senescence-associated (SA)
β-galactosidase (SA-β-gal) analysis was performed to detect the difference
in apoptotic cells between Hep-3B cells with or without KDM5B knockdown.
The data were presented as the mean ± SD (n = 3), NS, not significant,
**P < 0.01, and *** P < 0.001. (DOCX 656 kb)
Fig. 8 Partial recovery of clonogenic potential in KDM5B-depleted HCC cells by inhibition of p15 and p27 induction. a Western blot analyses of
KDM5B, p15 and p27 protein expression in Hep-3B and Focus cells treated with si-NC, si-2531, co-transfection of si-2531 and si-p15 and co-transfection
of si-2531 and si-p27. b and c The restoration of clone formation in KDM5B-depleted Hep-3B and Focus cells by abolishment of p15 and p27 induction.
*, P < 0.05 and **, P < 0.01, respectively
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